Qicai Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qicai Xiao has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Liqian Gao
School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat‐Sen University Shenzhen China
9 shared publications - Shao Q. Yao
National University of Singapore
5 shared publications Fen Yang
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen 518107, China
4 shared publicationsMenghua Xiang
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University and Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
4 shared publications- Jun Shen
Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
3 shared publications Shizhe Zhou
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University and Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 55, 241-256
Sonotheranostic nanosideromycin eradicates bacterial biofilm infections via ultrasound-detonated ROS generation and ferroptosis-like death
Biofilm formation poses a severe challenge to antibacterial stewardship. While siderophore-antibiotic conjugates (termed as sideromycins) offer a promising solution, their efficacy is inherently limited by antibiotic resistance. To transcend this barrier, we pioneer a transformative siderophore-sonosensitizer conjugate through covalent linkage of a catechol siderophore to purpurin 18 (a sonosensitizer). This novel conjugate further self-assembles with iron(III) ions, forming the first-reported carrier-free nanosideromycin-an all-in-on iron-siderophore-sonosensitizer nanoplatform. This design enables ultrasound-denotated reactive oxygen species (ROS) generation and ferroptosis-like amplication. Capitalizing on bacteria-specific siderophore uptake and pH-responsive assembly/disassembly, the nanosideromycin enables precision delivery and active internalization of sonosensitizers into bacteria. This strategy permits real-time localization of infections via concurrent fluorescence/photoacoustic and magnetic resonance imaging. Upon ultrasound irradiation, dual antimicrobial mechanisms of sonosensitizer-mediated sonodynamic therapy and siderophore/iron-augmented sono-Fenton catalysis are stimuonously unleashed, synergistically tirggering an explosive ROS burst and potent ferroptosis-like bacterial death. As a result, mice with multidrug-resistant biofilm-induced pyomyositis were completely cured. Collectively, this first-in-class theranostic nanosideromycin integrates highly-targeted imaging diagnostics, cost-effective yet ultra-efficient ROS generation, and ferroptosis-like bacterial killing, establishing a paradigm-shifting strategy for biofilm therapy with spatiotemporal controllability.
- 1 January 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 55, 241-256
Top Cited PapersOpen AccessSonotheranostic nanosideromycin eradicates bacterial biofilm infections via ultrasound-detonated ROS generation and ferroptosis-like death
Biofilm formation poses a severe challenge to antibacterial stewardship. While siderophore-antibiotic conjugates (termed as sideromycins) offer a promising solution, their efficacy is inherently limited by antibiotic resistance. To transcend this barrier, we pioneer a transformative siderophore-sonosensitizer conjugate through covalent linkage of a catechol siderophore to purpurin 18 (a sonosensitizer). This novel conjugate further self-assembles with iron(III) ions, forming the first-reported carrier-free nanosideromycin-an all-in-on iron-siderophore-sonosensitizer nanoplatform. This design enables ultrasound-denotated reactive oxygen species (ROS) generation and ferroptosis-like amplication. Capitalizing on bacteria-specific siderophore uptake and pH-responsive assembly/disassembly, the nanosideromycin enables precision delivery and active internalization of sonosensitizers into bacteria. This strategy permits real-time localization of infections via concurrent fluorescence/photoacoustic and magnetic resonance imaging. Upon ultrasound irradiation, dual antimicrobial mechanisms of sonosensitizer-mediated sonodynamic therapy and siderophore/iron-augmented sono-Fenton catalysis are stimuonously unleashed, synergistically tirggering an explosive ROS burst and potent ferroptosis-like bacterial death. As a result, mice with multidrug-resistant biofilm-induced pyomyositis were completely cured. Collectively, this first-in-class theranostic nanosideromycin integrates highly-targeted imaging diagnostics, cost-effective yet ultra-efficient ROS generation, and ferroptosis-like bacterial killing, establishing a paradigm-shifting strategy for biofilm therapy with spatiotemporal controllability.
- 26 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113781
“Capture and kill” circulating fibrocytes by cisplatin prodrug loaded albumin disrupt the progress of pulmonary fibrosis in mice
- 26 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113781
“Capture and kill” circulating fibrocytes by cisplatin prodrug loaded albumin disrupt the progress of pulmonary fibrosis in mice
- Open Access
- 8 September 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 74, 541-554
Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies
- 8 September 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 74, 541-554
Open AccessRationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies
- Open Access
- 22 September 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1280190
Editorial: Prodrug design and therapeutic applications
Editorial: Prodrug design and therapeutic applications
- 22 September 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1280190
Open AccessEditorial: Prodrug design and therapeutic applications
Editorial: Prodrug design and therapeutic applications
- Open Access
A New Fluorescent Probe for Hydrogen Sulfide Detection in Solution and Living Cells
Since Hydrogen Sulfide (H2S) was recognized as a gas transmitter, its detection and quantification have become a hot research topic among chemists and biologists. In this area, fluorescent probes have shown great advantages: fast and strong response, low detection limit and easy manipulation. Here we developed a new fluorescent probe that detected H2S selectively among various bioactive and inorganic salts. This probe was based on the core structure of fluorescein and reacted with H2S through azide-reduction. Great linearity was achieved correlating fluorescence intensity and H2S concentrations in solution. The detection of H2S in cancer cells was also achieved.
Open AccessA New Fluorescent Probe for Hydrogen Sulfide Detection in Solution and Living Cells
Since Hydrogen Sulfide (H2S) was recognized as a gas transmitter, its detection and quantification have become a hot research topic among chemists and biologists. In this area, fluorescent probes have shown great advantages: fast and strong response, low detection limit and easy manipulation. Here we developed a new fluorescent probe that detected H2S selectively among various bioactive and inorganic salts. This probe was based on the core structure of fluorescein and reacted with H2S through azide-reduction. Great linearity was achieved correlating fluorescence intensity and H2S concentrations in solution. The detection of H2S in cancer cells was also achieved.
- Open Access
- 4 July 2023
- Published by MDPI AG in Preprints.org
A New Fluorescent Probe for Hydrogen Sulfide Detection in So-Lution and Living Cells
Since Hydrogen Sulfide (H2S) was recognized as a gas transmitter, its detection and quantifica-tion have become a hot research topic among chemists and biologists. In this area. fluorescent probes have shown great advantages: fast and strong responds, low detection limit and easy ma-nipulation. Here we developed a new fluorescent probe that detected H2S selectively among various bioactive and inorganic salts. This probe was based on the core structure of fluorescein and reacted with H2S through azide-reduction. Great linearity was achieved correlating fluores-cence intensity and H2S concentrations in solution. The detection of H2S in cancer cells was also achieved.
- 4 July 2023
- Published by MDPI AG in Preprints.org
Open AccessA New Fluorescent Probe for Hydrogen Sulfide Detection in So-Lution and Living Cells
Since Hydrogen Sulfide (H2S) was recognized as a gas transmitter, its detection and quantifica-tion have become a hot research topic among chemists and biologists. In this area. fluorescent probes have shown great advantages: fast and strong responds, low detection limit and easy ma-nipulation. Here we developed a new fluorescent probe that detected H2S selectively among various bioactive and inorganic salts. This probe was based on the core structure of fluorescein and reacted with H2S through azide-reduction. Great linearity was achieved correlating fluores-cence intensity and H2S concentrations in solution. The detection of H2S in cancer cells was also achieved.
- Open Access
- 27 February 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1137707
Amplifying the efficacy of ALA-based prodrugs for photodynamic therapy using nanotechnology
5-aminolevulinic acid (ALA) is a clinically approved prodrug involved in intracellular Heme biosynthesis to produce the natural photosensitizer (PS) Protoporphyrin IX (PpIX). ALA based photodynamic therapy (PDT) has been used to treat various malignant and non-malignant diseases. However, natural ALA has disadvantages such as weak lipophilicity, low stability and poor bioavailability, greatly reducing its clinical performance. The emerging nanotechnology is expected to address these limitations and thus improve the therapeutic outcomes. Herein, we summarized important recent advances in the design of ALA-based prodrugs using nanotechnology to improve the efficacy of PDT. The potential limitations and future perspectives of ALA-based nanomedicines are also briefly presented and discussed.
- 27 February 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1137707
Open AccessAmplifying the efficacy of ALA-based prodrugs for photodynamic therapy using nanotechnology
5-aminolevulinic acid (ALA) is a clinically approved prodrug involved in intracellular Heme biosynthesis to produce the natural photosensitizer (PS) Protoporphyrin IX (PpIX). ALA based photodynamic therapy (PDT) has been used to treat various malignant and non-malignant diseases. However, natural ALA has disadvantages such as weak lipophilicity, low stability and poor bioavailability, greatly reducing its clinical performance. The emerging nanotechnology is expected to address these limitations and thus improve the therapeutic outcomes. Herein, we summarized important recent advances in the design of ALA-based prodrugs using nanotechnology to improve the efficacy of PDT. The potential limitations and future perspectives of ALA-based nanomedicines are also briefly presented and discussed.
- 10 January 2023
- Published by Elsevier in Biomaterials
- Vol. 294, 122000
Biodegradable silica nanocapsules enable efficient nuclear-targeted delivery of native proteins for cancer therapy
- 10 January 2023
- Published by Elsevier in Biomaterials
- Vol. 294, 122000
Biodegradable silica nanocapsules enable efficient nuclear-targeted delivery of native proteins for cancer therapy
- Open Access
- 18 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (8) , 1-14
Novel 1-hydroxy phenothiazinium-based derivative protects against bacterial sepsis by inhibiting AAK1-mediated LPS internalization and caspase-11 signaling
Sepsis is a life-threatening syndrome with disturbed host responses to severe infections, accounting for the majority of death in hospitalized patients. However, effective medicines are currently scant in clinics due to the poor understanding of the exact underlying mechanism. We previously found that blocking caspase-11 pathway (human orthologs caspase-4/5) is effective to rescue coagulation-induced organ dysfunction and lethality in sepsis models. Herein, we screened our existing chemical pools established in our lab using bacterial outer membrane vesicle (OMV)-challenged macrophages, and found 7-(diethylamino)-1-hydroxy-phenothiazin-3-ylidene-diethylazanium chloride (PHZ-OH), a novel phenothiazinium-based derivative, was capable of robustly dampening caspase-11-dependent pyroptosis. The in-vitro study both in physics and physiology showed that PHZ-OH targeted AP2-associated protein kinase 1 (AAK1) and thus prevented AAK1-mediated LPS internalization for caspase-11 activation. By using a series of gene-modified mice, our in-vivo study further demonstrated that administration of PHZ-OH significantly protected mice against sepsis-associated coagulation, multiple organ dysfunction, and death. Besides, PHZ-OH showed additional protection on Nlrp3−/− and Casp1−/− mice but not on Casp11−/−, Casp1/11−/−, Msr1−/−, and AAK1 inhibitor-treated mice. These results suggest the critical role of AAK1 on caspase-11 signaling and may provide a new avenue that targeting AAK1-mediated LPS internalization would be a promising therapeutic strategy for sepsis. In particular, PHZ-OH may serve as a favorable molecule and an attractive scaffold in future medicine development for efficient treatment of bacterial sepsis.
- 18 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (8) , 1-14
Open AccessNovel 1-hydroxy phenothiazinium-based derivative protects against bacterial sepsis by inhibiting AAK1-mediated LPS internalization and caspase-11 signaling
Sepsis is a life-threatening syndrome with disturbed host responses to severe infections, accounting for the majority of death in hospitalized patients. However, effective medicines are currently scant in clinics due to the poor understanding of the exact underlying mechanism. We previously found that blocking caspase-11 pathway (human orthologs caspase-4/5) is effective to rescue coagulation-induced organ dysfunction and lethality in sepsis models. Herein, we screened our existing chemical pools established in our lab using bacterial outer membrane vesicle (OMV)-challenged macrophages, and found 7-(diethylamino)-1-hydroxy-phenothiazin-3-ylidene-diethylazanium chloride (PHZ-OH), a novel phenothiazinium-based derivative, was capable of robustly dampening caspase-11-dependent pyroptosis. The in-vitro study both in physics and physiology showed that PHZ-OH targeted AP2-associated protein kinase 1 (AAK1) and thus prevented AAK1-mediated LPS internalization for caspase-11 activation. By using a series of gene-modified mice, our in-vivo study further demonstrated that administration of PHZ-OH significantly protected mice against sepsis-associated coagulation, multiple organ dysfunction, and death. Besides, PHZ-OH showed additional protection on Nlrp3−/− and Casp1−/− mice but not on Casp11−/−, Casp1/11−/−, Msr1−/−, and AAK1 inhibitor-treated mice. These results suggest the critical role of AAK1 on caspase-11 signaling and may provide a new avenue that targeting AAK1-mediated LPS internalization would be a promising therapeutic strategy for sepsis. In particular, PHZ-OH may serve as a favorable molecule and an attractive scaffold in future medicine development for efficient treatment of bacterial sepsis.
- Open Access
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (31) , 6304-6306
Recent Advances in Strategies and Tools for Efficient Drug Discovery and Delivery - Part II
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (31) , 6304-6306
Open AccessRecent Advances in Strategies and Tools for Efficient Drug Discovery and Delivery - Part II